Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended-infusion versus traditional-infusion piperacillin-tazobactam for hospitalized adults with infection
ACTRN12613001129774Phase 4Completed
- Sponsor
- Fan Sheung Yin
- Start
- Dec 2013
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of piperacillin + tazobactam in bacterial disease and febrile neutropenia (FN) (2 arms), sponsored by Fan Sheung Yin. Primary endpoint: 14-day mortality rate. Started Dec 2013; status: completed.
02
Drugs
piperacillin + tazobactam
03
Conditions
bacterial diseasefebrile neutropenia (FN)
Beyond the preview
Go deeper on ACTRN12613001129774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613001129774.